Introduction
Pathogenic mycobacteria replicate intracellularly within macrophage phagosomes, which has for a long time led to the assumption that MHC class II-restricted CD4 ϩ T lymphocytes, producing type 1 cytokines, constitute the major protective effector population. However, a number of studies have made the case for an important role for CD8 ϩ T cells in antituberculous protective immunity in both mice and humans. Murine mycobacteria-specific CD8 ϩ T cell lines which were cytolytic in vitro for macrophages infected with tubercle bacilli (1) or protected mice against Mycobacterium lepraemurium infection have been described (2, 3) . Mice devoid of MHC class I-restricted CD8 ϩ T cells due to β 2 -microglobulin gene disruption died quickly after M. tuberculosis infection (4), whilst in vivo depletion of CD8 ϩ T cells with antibodies resulted in impaired resistance to M. tuberculosis infection (5) and decreased protection in Mycobacterium w vaccinated mice (6) .
Human mycobacteria-specific CD8 ϩ T cells have also been described (7, 8) , CD8 ϩ T cell clones have been established (9) and the case of a patient with isolated CD8 ϩ T cell deficiency who suffered from frequent tuberculosis relapses has been reported (10) . A protective role of CD8 ϩ T cells in human tuberculosis has been argued on the grounds that the number of CD8 ϩ T cells was significantly elevated in sections from patients with lymph node tuberculosis, a form of disease which can resolve without chemotherapy (11, 12) . CD8 ϩ T cells were not only present in large numbers within granulomata but also formed a sheath layer at the border between the granuloma and the lymphocytic mantle (11) which might indicate that CD8 ϩ T cells are instrumental in limiting the immunopathologic process. This is also supported by the description of hugely enlarged granulomata in M. tuberculosis infected β 2 -microglobulin knockout mice devoid of CD8 ϩ T cells (4) . Data on the identity of mycobacterial antigens recognized by CD8 ϩ T cells is limited and very few cytotoxic T lymphocyte (CTL) epitopes have been characterized. Identification of such antigens and their respective peptide epitopes could be useful for investigating the precise role of CD8 ϩ T cell responses in tuberculosis and could also lead to the develop-ment of effective tuberculosis vaccines. In this study we identified the M. tuberculosis 38 kDa glyco-lipoprotein (13, 14) as a target molecule for CD8 ϩ CTL responses and determined its peptide epitopes in H-2 b mice. Our results indicate major variations in the epitope specificities recognized after different modes of immunization and infection.
Methods

Mice
Female C57BL/6 (H-2 b ) mice were purchased from the Biological Services Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London and used in the experiments when 7-10 weeks old.
Synthetic peptides
Peptides were synthesized by simultaneous multiple peptide synthesis using Fmoc technology as described earlier (15) . Homogeneity was confirmed by analytical HPLC and, for the majority of peptides, by mass spectrometry. A set of pinsynthesized peptides (PEPSCAN, peptides: 10mers overlapping by six residues) covering the complete sequence of the 38 kDa protein was purchased from Chiron Mimotopes (Clayton, Australia).
Plasmids
The gene encoding the 38 kDa protein was cloned into the expression vector pcDNA3 (Invitrogen, San Diego, CA) under the control of the cytomegalovirus promoter. The plasmid pXJ38 was obtained by subcloning a 1.2 kb NdeI-BamHI fragment derived from pMS10.4 (16) , that encoded the 38 kDa protein of M. tuberculosis, into the EcoRV site of pcDNA3.
Cell transfection
Transfectants EX38 and RX38 were generated by transfecting EL4, a chemically induced thymoma of C57BL/6 origin, and RMA, a Rauscher virus-induced T cell lymphoma of C57BL/ 6 origin with plasmid pXJ38. All transfectants were selected with G418 at a concentration of 1 mg/ml and cloned twice by limiting dilution before being used in the experiments. Expression of the 38 kDa protein was confirmed by RT-PCR and Western blotting of cell lysates using the 38 kDa antigenspecific mAb TB71 (13).
Recombinant vaccinia virus
A recombinant vaccinia virus expressing the 38 kDa protein (Vac38) was generated by inserting the coding sequence of the 38 kDa protein into the vaccinia virus recombinant plasmid pSC11 resulting in the plasmid pSC11/38. Recombinant vaccinia viruses were produced by transfection of pSC11/38 into 143 cells infected with wild-type vaccinia virus followed by selection for recombinant viruses. Vac38 was purified by repeated plating (4 times) and protein expression was confirmed by Western blot using the mAb TB71 (13) .
Peptide-binding assay
RMA-S cells were incubated overnight at room temperature to enhance class I MHC molecule expression and then cultured in triplicates with 200 µM peptide in culture medium (RPMI 1640 supplemented with 10% FCS, 50 µg/ml gentamicin, 2 mM L-glutamine and 5ϫ10 -5 M 2-mercaptoethanol) in round-bottomed 96-well plates for 1 h at 37°C as described earlier (17) 
Induction of CTL
Splenocytes from immunized or vaccinated mice (see above) were cultured in 24-well plates at a density of 5ϫ10 6 / well. Complete culture medium contained RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine and 5ϫ10 -5 M 2-mercaptoethanol. Then, 5ϫ10 5 irradiated RX38/ well were added to the splenocytes from M. tuberculosis infected or nucleic acid vaccinated mice. Cells from mice immunized with tumour cells were stimulated with 5ϫ10 6 p.f.u. of Vac38/ well. After 5-7 days, responding cells were used in 51 Cr-release assays. To produce CTL lines, T cells were restimulated every second week by culturing 5ϫ10 4 responder cells/well together with 5ϫ10 5 EX38/well. Each well also received 4ϫ10 6 irradiated syngeneic splenocytes as feeders and 10 U/ml rIL-2 (Genzyme, Cambridge, MA). To produce clones from these lines, T cells were then plated in 96-well round-bottom plates at 0.5, 5 and 20 cells/well with 10 4 EX38/ well, feeder cells (2ϫ10 5 cells/well) and rIL-2 (10 units/well).
CTL assay
Target cells EL4, RMA, RX38 or EX38 were labelled with 51 Cr (50 µCi; Amersham, Amersham, UK) at 37°C for 1 h. Then, 5ϫ10 3 labelled target cells were plated into wells of 96-well round-bottom plates which contained serial dilutions of effector T cells in a total volume of 200 µl/well. After 4-6 h incubation at 37°C, 100 µl supernatant/well was collected and radioactivity counted in a LKB γ-counter. Synthetic peptides derived from the sequence of the 38 kDa protein were tested by incubating 100 µM of each peptide with 5ϫ10 3 51 Crlabelled EL4 cells for 1 h before effector cells were added. HPLC separated peptides from whole cell lysates were tested by incubating 10 µl peptide solutions/fraction with 5ϫ10 3 51 Cr-labelled EL4 cells for 1 h before addition of the effector cells. In some assays, blocking anti-CD4 mAb (clone RM4-5) or anti-CD8 mAb (clone 53-6.7) (both from PharMingen, San Diego, CA) were added (5 µg/well) to the effector cell population 30 min before 51 Cr-labelled target cells were added (18) . Specific lysis ϭ (experimental release -spontaneous release/maximum release -spontaneous release)ϫ100%. Spontaneous release was 10% or less.
Peptide elution from cell lysates
Peptides were eluted from EL4 and EX38 cells and separated by HPLC. Cells (2.5ϫ10 8 ) were suspended in 3 ml 0.7% trifluoroacetic acid (TFA) and ultrasonicated (Soniprep150) 3 times each for 30 s, followed by centrifugation at 27,000 g, 4°C for 1 h. The supernatants were subjected to centrifugation in Centricon filters (10 kDa cut-off) at 5000 g, 4°C for 3 h. The filtrates containing peptides Ͻ10 kDa were separated on a reverse-phase HPLC column (SuperPac Pep-S, column 250ϫ4.0 mm, C18; Pharmacia LKB, Bromma, Sweden). Buffer A was 0.1% TFA in H 2 O and Buffer B was 0.1% TFA in acetonitrile. For peptide elution, the acetonitrile concentration was increased from 0 to 40% at a gradient of 1%/min. Dried fractions were dissolved in 100 µl PBS and sonicated for 5 min before used in CTL assays.
Cytokine ELISA
In vitro IFN-γ and IL-4 production in culture supernatants was determined by ELISA using mAb from PharMingen as described earlier (19) .
Results
Tumour cell lines and recombinant vaccinia viruses expressing the mycobacterial 38 kDa protein
Transfection of the MHC class II-negative tumour cell lines EL4 and RMA (both H-2 b ) with the plasmid pXJ38, carrying the gene encoding for the M. tuberculosis 38 kDa protein, produced stable transfectants designated EX38 and RX38 respectively. A recombinant vaccinia virus also expressed this protein (Vac38). In order to demonstrate protein expression, lysates of EX38, RX38 and of cells infected with Vac38 were subjected to SDS-PAGE and immunoblots developed with the 38 kDa protein-specific mAb TB71 (13) . The results demonstrated that both EX38 and RX38, as well as cells infected with Vac38, express high levels of the mycobacterial protein (Fig. 1) . The 38 kDa antigen expressed in eukaryotic cells was detected as two distinct bands, one with a slightly higher mol. wt (40 kDa) than that of the protein found in M. tuberculosis culture filtrates. When we stained these membranes for carbohydrate components we found that the 38 kDa protein, when expressed by eukaryotic cells, is not glycosylated (data not shown). This is in contrast to the protein expressed in mycobacteria, which has been described as glycoprotein (20) . It is possible that the prokaryotic secretion signal peptide, which is removed during secretion into bacterial culture supernatants, is retained in the eukaryotically expressed protein, thus accounting for its higher mol. wt. The second, smaller, band of~35 kDa could be a degradation product. We subsequently used these reagents to (i) immunize mice (EX38), (ii) to expand CTL effector cells in vitro (EX38, RX38 and Vac38) and (iii) as 51 Cr-labelled target cells in CTL assays (EX38 and RX38).
The 38 kDa protein is a target for CD8 ϩ CTL
We employed three immunization strategies to induce CTL in C57BL/6 mice, i.e. i.p. injection of the transfected line EX38, nucleic acid immunization with pXJ38 and i.p. infection of mice with tubercle bacilli. All three approaches were successful since we detected strong CTL responses in each case ( Fig. 2A-C) . Only mAb specific for CD8 effectively blocked specific lysis, whilst mAb to CD4 did not (Fig. 2D) . In vitro stimulation of naive spleen cells with RX38 or EX38 for the same periods did not lead to significant cytolytic responses (data not shown).
Identification of peptide epitopes recognized by CD8 ϩ CTL
The specificity of long-term lines derived from the CTL populations described in the preceding section was tested using a collection of 92 10mer peptides, overlapping by six residues which covered the whole sequence of the 38 kDa protein (PEPSCAN).The specificity patterns of CTL derived from EX38-and DNA-vaccinated mice showed differences (Fig. 3) : EX38-induced cells recognized peptides in the regions of amino acid residues 129-138 and 312-322 (Fig. 3A) , whereas the nucleic acid vaccine-induced CTL recognized only peptides in the area between residues 129 and 138 (Fig. 3B) .
In view of possible structural limitations of this set of peptides, e.g. non-optimal length, insufficient quantities, gaps in sequence coverage due to six residue overlap, we examined also a set of 12 peptides which were predicted to contain H-2K b or H2-D b binding motifs (21) (for sequences see Table  1 ). These predictions were validated using the RMA-S cellular binding assay which showed that all peptides bound to either H-2K b or H2-D b or both (Table 1) .
These peptides were now used to sensitize EL4 cells in 51 Cr-release assays employing effector cell lines derived from DNA vaccinated, EX38 vaccinated or infected mice. The results are shown in Table 1 , and demonstrate that CTL from EX38-immunized mice recognized peptides with amino acid residues 129-137, 191-199, 225-234, 309-318, 312-319 and 317-325, whereas CTL from DNA-vaccinated mice recognized peptides 129-137, 243-250 and 312-319, but CTL from M. tuberculosis-infected mice recognized only one peptide (residues 225-234). The peptide recognition patterns of these CTL lines were established repeatedly over a period of several weeks and proved to be stable.
Subsequently, 26 T cell clones were established from the CTL line derived from EX38 vaccination which recognized the widest range of tested peptides. These clones recognized EX38, but not EL4 cells alone. They could be divided broadly into three groups on the grounds of their peptide specificity and the results of three representative clones are given in (Table 2) , which corresponds to a Tc1 profile.
Recognition of naturally processed peptides
To complement the epitope analysis, naturally processed peptides from EX38 cells were isolated. The cells were lysed in acid, which results in the denaturation of MHC molecules, and lower mol. wt peptides were separated by HPLC. HPLC fractions were collected (data not shown), dried by vacuum and tested with the T cell clones established from EX38 immunized animals (see above and Table 2 ). Results obtained with three representative clones are shown in Fig. 4 . We found that the majority of clones (represented by clone 6R.7), with specificity for peptide 129-138, recognized HPLC fraction 29, whereas clones specific for peptide 312-319 (represented by clone 6R.44) reacted with fraction 31. This indicates that the peptides recognized by these clones were produced by natural processing. Interestingly, the clone 6R.27, which recognized none of the motif peptides (Table 2 ), was nevertheless able to lyse cells sensitized with HPLC fraction 29, thus indicating that more than one, yet to be described, 38 kDaderived peptide is present in this fraction (Fig. 4) .
Discussion
The results in this paper demonstrate that the M. tuberculosis 38 kDa glyco-lipoprotein is a target for murine MHC class Irestricted CD8 ϩ CTL and therefore suggest that this protein gains access to the MHC class I presentation pathway. The specificity of CD8 ϩ T cells in mycobacterial infections has previously not been determined aside from reports describing a RMA-S binding assay as described in Methods. Mean fluorescence with peptide/mean fluorescence medium ϭ 3-5.9, ϩ; 6-10, ϩϩ; Ͼ10, ϩϩϩ.
b51 Cr-release assay as described in Methods. C57BL/6-derived effector CTL populations: EX38/1ϭ induced by immunization with transfected EX38; DNA/1ϭ induced by nucleic acid vaccination; TB/1ϭ induced by M. tuberculosis infection. E:T ratio ϭ 10:1. Positive values in bold. the mycobacterial stress protein hsp65 and some of its epitopes (22, 23) . Indeed, this paper is the first study to conduct a comprehensive analysis of the constituent CTL epitopes.
Antigen-specific CTL responses were induced by immunization with either transfected cells or DNA vaccination. These data corroborate the induction of CTL and protective immunity by mycobacterial hsp65 transfectant immunization (24, 25) , or nucleic acid vaccination with mycobacterial hsp65 or Ag85A (23, 26) . We have recently demonstrated that the 38 kDa DNA vaccine is inducing protective immunity in vaccinated mice to challenge with virulent tubercle bacilli resulting in a reduction of bacterial loads by up to 1 log, which is of the same order of magnitude as that following BCG vaccination (27) .
Nucleic acid vaccination by intramuscular injection is characterized by antigen expression in muscle cells. However, recent studies have demonstrated that antigen is transferred from myocytes to bone marrow-derived antigen-presenting cells (APC) which are necessary to induce a CTL response after DNA vaccination (28) (29) (30) . Antigen taken up by the APC may be processed via an exogenous pathway of class I presentation (31) , which might result in the observed distinct CD8 peptide specificity induced by DNA immunization. Intracellular tubercle bacilli are contained in phagosomes (32, 33) and do not enter the cytosol. Yet M. tuberculosis infection evokes transport of antigens like ovalbumin to the cytosol followed by TAP-dependent presentation to CD8 ϩ T cells (34) . Restricted release of mycobacterial constituents out of phagosomal vacuoles results in limited intersection with the endocytic pathway (35, 36) and antigens, like the 38 kDa protein, which are actively secreted by the pathogen, might be preferentially included in such vesicles. These mycobacterial antigens could also be processed in phagocytic compartments and enter a recently described phagosome-to-cytosol pathway (37) . Alternatively, processed peptides could be regurgitated into the media to bind to surface class I molecules (38) . Infection of macrophages with tubercle bacilli can inhibit to a certain degree MHC class II antigen processing (39, 40) , concomitant with facilitated MHC class I presentation to CD8 ϩ CTL (34). Our results demonstrating diverse CD8 peptide specificities suggest at least quantitative differences in peptide presentation between infected and transfected target cells.
We used three approaches to identify the peptide sequences of CTL epitopes, i.e. (i) an empirical method using overlapping peptides, (ii) prediction of sequences on the basis of well established motifs (reviewed in 21) and (iii) elution of naturally processed peptides from transfected tumour cells. Table 1 for sequences) were incubated with the CTL clones at an E:T ratio of 5:1. Peptide specificities of clones are indicated in brackets. Lysis of EL4 cells without peptides was 3% or less for all clones. Lysis of EL-4 with any peptide alone was 1.5% or less.
b IFN-γ and IL-4 in supernatants was determined by ELISA after 2 days of culture in the presence of EX38. c Representative of 23 out of 26 CTL clones.
The comprehensive procurement of overlapping peptides to cover all specificities would carry a prohibitive cost. Therefore, it is gratifying that prediction of epitopic peptides was successful. The predictive power of these motifs was proved by the fact that almost all predicted peptides used in this study did bind to H-2K b or H2-D b molecules. Several peptides were found to bind to both H-2K b and H-2D b . This is an interesting observation given the allele specificity of the predictive motifs (21), though such binding characteristics have been reported for peptides derived from the papilloma virus E6 and E7 proteins (17) . We deliberately synthesized peptides which did not always have perfect motifs, e.g. p129-138, which proved to be the most prominently recognized determinant in this study. Hence, a strict adherence to the motif sequences would have missed this epitope. Other ligands not fitting to a standard motif have been recently described (41) . The third approach, elution of peptides from target cell lines followed by HPLC separation, confirmed that the two major epitopes identified by motif peptides are also processed in vivo.
Could peptides, such as those described in this study, be used in peptide-based vaccines? One precedent is a CTLinducing peptide from Listeria monocytogenes which protects mice against lethal infection (42) . It is also encouraging that all T cell clones analysed in this paper, regardless of their specificity, produced large amounts of IFN-γ, a cytokine believed to be of critical importance in the protective antituberculous immune responses (43, 44) . We are now testing the protective capacity of the peptides described in this study using 'minigene' constructs expressed either as DNA vaccine or as recombinant vaccinia virus (45) (46) (47) . However, in view of the polymorphism of HLA alleles, it will almost certainly be necessary to include several different peptides to allow effective coverage of the whole population. In view of the importance of CD4 ϩ T cells in anti-tuberculous immunity, inclusion of epitopes recognized by CD4 ϩ T cells will also be mandatory. Most immunodominant mycobacterial CD4 epitopes are recognized in the context of multiple MHC class II alleles (48) and promiscuous peptides recognized in the context of multiple class I alleles have also been described (49, 50) . However, the extent of genetic restriction of CD8 ϩ T cell responses against the 38 kDa protein is yet to be determined. Recent comparative data on peptide binding to various human class I MHC molecules suggested that the majority of HLA-A and -B alleles world-wide can be grouped into four major HLA supertypes (supermotifs) defined by their broad peptide binding specificities (51) . Thus, it is hoped that MHC class I polymorphism may be functionally much more limited, enabling broad population coverage using fewer peptides than originally forecast. Nevertheless, whilst the identification of the relevant peptides may contribute to the development of a potent subunit vaccine, it may be prudent to acknowledge that this objective is associated with a range of complexities concerning, e.g. the optimal structural formulation and modes of vaccine delivery.
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